Magellan and Charles River Laboratories Partner on Zelestrocel Advancement
What happened
Magellan Stem Cells and Charles River Laboratories have partnered to advance Zelestrocel, a regenerative medicine candidate. The collaboration focuses on biologics quality control and viral and release testing under current good manufacturing practice standards. Magellan recently finished Phase I/II clinical studies for the stem cell therapy and is preparing to begin a pivotal Phase III clinical program. Charles River Laboratories will provide viral safety assessments using next-generation sequencing for cell and gene therapy.
Why it matters
The partnership supports the progress of Zelestrocel toward international regulatory standards, including those set by the European Medicines Agency and the Food and Drug Administration. This collaboration expands Charles River Laboratories' GMP testing capabilities in the high-value cell and gene therapy sector.
Who's involved
- MagellanAustralian biotechnology firm partnering to advance the regenerative medicine candidate Zelestrocel.
- Charles River LaboratoriesMajor US biomedical company providing quality control and viral safety testing for the partnership.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Charles River LaboratoriesSpeculative
Charles River Laboratories could see increased revenue or market share due to the expansion of its core GMP testing capabilities in the high-value cell and gene therapy sector.
Keep exploring
The entities involved
-
Magellan
Polish business
Nothing else this week.
-
Charles River Laboratories
major US biomedical company
Nothing else this week.